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Life can only be understood backwards; but it must be lived forwards 
                Søren Kierkegaard 
 
  
ABSTRACT 
 
Adjuvant endocrine therapy improves breast cancer survival, unconditional of other 
treatment. In premenopausal breast cancer, tamoxifen for 5 years is the standard 
treatment, with or without the addition of ovarian ablative therapy. The optimal timing 
and duration of ovarian ablative treatment is not yet defined, and it is not clear if there 
is additional benefit from ovarian suppression in combination with cytotoxic 
chemotherapy. With improving survival and excellent prognosis, there is increasing 
need for prevention of long-term adverse effects, monitoring and treatment when 
appropriate. Premature ovarian failure is frequent from adjuvant treatment of young 
breast cancer patients with a following risk of accelerated bone loss and infertility. The 
possible ovarian protective effect of ovarian ablation from luteinizing hormone-
releasing hormone (LHRH) agonists is debated.  
Aims: The purpose of our study is to examine the efficacy of the LHRH agonist 
goserelin for adjuvant therapy of premenopausal breast cancer, the role of interaction 
between goserelin and tamoxifen and the impact of estrogen receptor (ER) content. We 
also examine long-term side effects in regard to ovarian function and bone health. 
Patients and methods: The study was designed to determine whether the addition of the 
LHRH agonist goserelin and/or tamoxifen to adjuvant therapy provided benefit for 
premenopausal women with breast cancer. Patients were entered into a 2 x 2 factorial 
randomisation to tamoxifen 40 mg daily with or without concomitant goserelin, 3.6 mg 
every 28 days or goserelin alone for 2 years. Efficacy was analysed as well as the 
effects on ovarian function, bone mineral density and bone markers.  
A total of 927 women were recruited to the Stockholm part of the ZIPP trial. At a 
median follow-up of 12.3 years, goserelin reduced the risk of first event by 32% (P = 
0.005) in the absence of tamoxifen, and tamoxifen reduced the risk by 27% (P = 0.018) 
  
in the absence of goserelin. The combined goserelin and tamoxifen treatment reduced 
the risk by 24% (P = 0.021) compared with no endocrine treatment. In highly ER-
positive tumours, there were 29% fewer events among goserelin-treated patients (P = 
0.044) and a trend towards greater risk reduction, depending on the level of ER content. 
The greatest risk reduction from goserelin treatment was observed among those not 
receiving tamoxifen (HR: 0.52, P = 0.007). In the study of ovarian function, 36% of the 
women in the goserelin group reported menses one year after completed CMF- and 
endocrine therapy, compared to 7% in the goserelin plus tamoxifen group, 13% in the 
tamoxifen group and 10% of the controls. Among women treated with goserelin, there 
was a statistically significant increase in the proportion of menstruating women one 
year after completed treatment, compared to at 24 months of treatment (P = 0.006), in 
contrast to all other treatment groups, who were unchanged or more often amenorrheic. 
The bone mineral study showed that after 2 years of treatment, there was a significant 
decline in bone mineral density (mean change, -5%; P < 0.001) in the women receiving 
goserelin. The combined goserelin and tamoxifen treatment, as well as tamoxifen 
alone, resulted in a lesser, but statistically significant, decrease in bone mineral density 
(mean change, -1.4%; P = 0.02; and -1.5%; P < 0.001). One year after cessation of 
treatment, the goserelin group alone showed partial recovery from bone loss (mean 
change, 1.5%; P = 0.02). In the study of bone turnover markers (BTM), there was a 
significant rise in Osteocalcin (RR: 1.57, p < 0.001), PINP (RR 1.65, p < 0.001) and 
CTX (RR 1.98, p < 0.001) among goserelin-treated patients. There were no significant 
changes in BTM among those treated with either goserelin and tamoxifen or tamoxifen 
alone. Among patients where bone mineral density measurements were available, 
change in BMD was inversely associated with change in BTM (r = -0.40 to -0.51).  
Conclusions: Adjuvant tamoxifen in combination with the LHRH agonist goserelin is 
not superior to either tamoxifen alone or goserelin alone in regard to recurrence-free 
  
survival in premenopausal endocrine responsive breast cancer. A significant interaction 
indicates that the effect of goserelin depends on whether tamoxifen is given or not, and 
the effect of tamoxifen depends on whether goserelin is given or not. In this study there 
is a trend towards greater efficacy of goserelin with increasing ER levels. A subgroup 
of women with strongly ER-positive tumours benefits more from goserelin treatment, 
whereas the benefit of tamoxifen does not seem to be dependent on ER content. This 
study shows some evidence of a protective effect of goserelin on ovarian function in 
CMF treated women. This effect was not observed where tamoxifen was given in 
addition to goserelin treatment. Further studies are needed to confirm this. Two years of 
ovarian ablation from goserelin treatment induces a significant reduction in bone 
mineral density, but there is partial recovery from the bone loss one year after stopped 
treatment. After six months of goserelin treatment, markers of both bone resorption and 
bone formation increase, whereas there is no change in bone turnover from tamoxifen 
alone or in combination with goserelin. Furthermore, there an inverse correlation of 
changes in BMD and bone markers. The addition of tamoxifen seems to counteract the 
effects of goserelin on BMD and BTM. In addition to BMD measurements, 
biochemical examinations of bone turnover markers may be useful for monitoring bone 
health, identifying women at risk for bone loss and making early interventions possible. 
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1 INTRODUCTION 
 
Breast cancer is the commonest cancer among women and the leading cause of death in 
women, aged 35-54 years 
1
. Although the median age for breast cancer is over 60 years, 
around 25% of the women are below 50 years of age at the time of diagnosis 
2
. Breast 
cancer at a young age has aggressive biological behaviour more often and is associated 
with poorer prognosis in comparison to older women 
3, 4
. Tumours in younger women 
tend to have higher grades and proliferation markers and are more often hormone 
receptor negative and human epidermal growth factor receptor 2 (HER-2) positive, than 
tumours in older women 
5-7
. Similarly to other Western countries, breast cancer 
incidence in Sweden has increased at an average of 1.3 per cent annually over the last 
20 years 
2
. At the same time, survival after breast cancer diagnosis has been constantly 
improving, due to several possible factors, such as the introduction of mammography 
screening, improved radiotherapy techniques, more potent cytotoxic and targeted drugs, 
as well as improved endocrine treatment. In spite of the continuously evolving 
treatment for early breast cancer in the last decades, resulting in better prognosis and 
better control of side effects, the optimal adjuvant therapy for premenopausal women is 
yet to be defined
8-10
. Furthermore, frequent long-term side effects among young women 
include premature menopause, infertility and bone loss, among other quality of life 
(QoL) issues needing to be addressed. As more women have excellent prognoses after 
adjuvant therapy, a greater effort is necessary to assure physical and psychological well 
being after treatment.  
 2 
 
1.1 ADJUVANT BREAST CANCER TREATMENT  
 
Adjuvant therapy in breast cancer has proven to be effective in regard to disease-free 
survival as well as overall survival, unconditional of age or menopausal status. 
International guidelines, such as the St. Gallen International Expert Consensus, 
recommend several prognostic and predictive factors in order to select optimal 
treatment after surgery
11-14
. In addition to assessment of tumour size and axillary lymph 
node status, analysis of estrogen- and progesterone receptor content, HER-2 expression, 
vascular invasion and the proliferative marker Ki-67 are recommended as standard 
assessment 
12
. Using these clinicopathological parameters, breast cancer subtypes can 
be classified for systemic therapy recommendations (Table 1). According to the 
guidelines, hormone receptor positivity, HER-2 negativity and low Ki-67 are classified 
as Luminal A type, hormone receptor positive, HER-2 positive/negative and high Ki-67 
as Luminal B type, hormone receptor negative, HER-2 positive as HER-2 positive (non 
luminal) type and hormone receptor negative, HER-2 negative as Triple negative type. 
In hormone receptor positive disease, endocrine therapy is a central part of the adjuvant 
treatment, with or without cytotoxic chemotherapy and/or radiotherapy. The efficacy of 
chemotherapy has been proven since the early studies of cyclophosphamide, 5-
fluorouracil and methotrexate (CMF) therapy in the 1970s, later succeeded by 
anthracycline-based treatment and then with the addition of taxanes, survival has 
improved step by step 
15-18
. In most studies, the benefit of chemotherapy is greatest 
among younger women, and is less as age advances 
16, 17
. The recommended timing of 
cytotoxic chemotherapy is before endocrine and/or radiotherapy because the risk of 
increased adverse effects and possible interactions. Endocrine treatment is given 
concomitantly or after radiotherapy, according to local practise since concomitant 
treatment seems to be safe
19
. Radiotherapy, which is generally recommended following 
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breast-conserving surgery, and in some cases after mastectomy, is not only highly 
effective in regard to local recurrences, but improves survival as well 
20
.  
 
Table 1. Systemic treatment recommendations for breast cancer subtypes (Adapted 
from St. Gallen International Expert Consensus on the Primary Therapy of Early Breast 
Cancer 
12
). 
 
 
1.2 STEROID HORMONE RECPETORS  
 
Estrogen plays a fundamental role in the pathogenesis and development of breast 
cancer. Treatment aimed at reducing circulating estrogen has proven to be highly 
beneficial to women after breast cancer diagnosis and surgery. The estrogen receptor 
(ER) was discovered in the 1960s and led to subsequent findings that breast cancer 
growth is regulated by estrogen action via the ER 
21
. The identification of ER has been 
of extreme measures in regard to the development of treatment options in breast cancer. 
Evaluation of ER status is recommended as a part of the routine assessment of a 
tumour, based on the ER content being a major prognostic as well as predictive 
biomarker for endocrine therapy 
22, 23
. In premenopausal women, ER positive tumours 
are somewhat less frequent or approximately 60% 
24, 25
. Around 75% of all tumours 
express steroid hormone receptors and about 60% of ER positive tumours respond to 
endocrine therapy 
26, 27
.  
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1.2.1 Methods of ER assessment 
 
There have been mainly two methods used to assess the content of ER, i.e., quantitative 
analysis of ER (Figure 1) by ligand-binding assay (LBA) and immunohistochemical 
assessment (IHC). 
 
1.2.2 Ligand-binding assay 
 
LBA is based on isoelectric focusing of estradiol receptor protein from human 
mammary carcinoma in polyacrylamide gel or sucrose gradient analysis and requires 
fresh-frozen tumour tissue 
28
. Values between 0 and 1000 femtomoles (fmol) per 
milligram (mg) of Protein have been reported, although a cut-off point of 3 to 10 
fmol/mg Protein have often been used for defining ER positive tumours by this method, 
although some have used levels above 0.05 fmol/µg DNA. LBA was the former 
standard method and widely validated for estimating ER content. The main advantages 
of the LBA assay are the quantitative measurements with reproducibility as well as 
good quality control. There are, however, some disadvantages, namely that the method 
requires fresh tumour tissue, is relatively expensive and is not very specific for tumour 
cells only. On these grounds, LBA has mostly been replaced by IHC, which is currently 
the standard method 
29
. 
 
1.2.3 Immunohistochemical assessment 
 
IHC is based on the use of highly specific monoclonal antibodies binding to the ER. 
The IHC method is at present more commonly used than LBA, as it is less expensive, 
easier to perform, useful on a wider variety of tumour tissue and is more sensitive as 
well as specific for staining tumour cells only. As little as 1% staining cells are defined 
as ER positive by the American Society of Clinical Oncology (ASCO), although 10% 
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staining cells has been used as a cut-off for positivity in a variety of studies. Recently, 
the St. Gallen Consensus Conference declared a tumour with any staining cells as ER 
positive 
12
. In spite of the differences in the techniques, there is high concordance 
between the LBA and IHC methods, both in relation to ER status and clinical outcomes 
30-34
. 
 
 
Figure 1. Immunohistochemical assessment of the estrogen receptor in tumour tissue. 
ER positive cells show a brown signal of nuclear intensity (score + to +++). 
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1.3 ADJUVANT ENDOCRINE THERAPY 
 
The role of estrogen suppression has been known for a long time and goes back to the 
Scottish surgeon George Beatson‘s report in 1896 on the effect of bilateral 
oophorectomy in metastatic breast cancer 
35
. However, there was over half a century of 
delay until the discovery of the ER 
36
, and it became clear that the presence of ER 
indicated that the tumour was dependent on estrogen and tumour response could be 
controlled by endocrine manipulation
21, 37
. Luteinizing hormone–releasing hormone 
(LHRH) synthetic agonists were developed in the 1970s, allowing reversible ovarian 
function suppression. Again, there was a delay until the 1990s before a definite survival 
advantage was established for adjuvant ovarian suppression (OS) in premenopausal 
breast cancer 
38
. Tamoxifen was introduced in the late 1960s and has since been studied 
extensively. Tamoxifen, a drug originally intended for contraception but failed as such, 
interferes with the activity of estrogen by competitive binding to the ER. The anti-
fertility properties in rats led to the hypothesis of the drug's anti-breast cancer properties 
39, 40
. In later clinical trials, tamoxifen proved to be highly effective, and the drug has 
now been in clinical use for over 30 years. In spite of extensive research through the 
last decades, there are some unanswered questions regarding endocrine treatment in 
premenopausal women, such as whether OS in combination with tamoxifen is 
beneficial, the timing and duration of OS, as well as the additional benefit of OS in 
combination with cytotoxic chemotherapy. 
 
1.3.1 Tamoxifen 
 
Tamoxifen is the first successful targeted therapy in cancer and is listed as an essential 
medicine by the World Health Organisation. Tamoxifen is in a class of selective 
estrogen receptor modulators (SERMs), having tissue-dependent as well as species-
dependent effects. For example, tamoxifen has a pure antiestrogenic effect in chicks 
41
. 
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In humans, however, tamoxifen has an antiestrogenic effect in some tissues and an 
estrogenic effect in other tissues. The antiestrogenic effects are most prominent in 
breast tissue and the vagina, where tamoxifen reduces glandular as well as epithelial 
development 
42, 43
. The antiestrogenic effect on breast tissue decreases the risk of 
primary or contralateral breast cancer 
44, 45
. Among the antiestrogenic effects of the 
drug are also vasomotor symptoms, such as hot flushes. However, in some tissues the 
estrogenic effects of tamoxifen are dependent on menopausal status. Among 
postmenopausal women, estrogenic effects are prominent in the uterus, the 
cardiovascular system as well as bone, whereas the main effect on bone in 
premenopausal women is antiestrogenic 
46-54
. The enzyme cytochrome P450 2D gene 
(CYP2-D6) is responsible for the conversion of tamoxifen to endoxifen, which is the 
active metabolite of tamoxifen 
55
. There are known inherited variants of CYP2-D6, 
which may influence both the magnitude of efficacy as well as side effects of tamoxifen 
56
. In premenopausal women, estrogenic effects lead to decreased concentrations of the 
gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH) 
57, 58
. 
Tamoxifen was early on shown to have antitumor effects in both pre- and 
postmenopausal breast cancer, but there was a several decades delay until it became a 
standard therapy in the premenopausal setting
59
 . Tamoxifen with or without OS is still 
the standard endocrine treatment in premenopausal breast cancer 
12
. The more recent 
aromatase-inhibitors (AIs) treatment is not effective in women with hormonal 
production from the ovaries 
14
. The role of AIs in combination with OS in the 
premenopausal setting is under investigation. 
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Figure 2. The structural formula of Tamoxifen 
 
1.3.1.1 Duration and dosage of tamoxifen 
 
Originally, tamoxifen was used for 1 year of adjuvant therapy after surgery, based on 
existing experience from advanced breast cancer treatment and average duration of 
response before drug resistance developed 
60, 61
. Subsequent trials showed that 2 years 
were better than 1 year and later, 5 years were proven to be better than 2 years of 
treatment 
61-63
. In the early clinical trials, the daily dose of tamoxifen varied from 10 to 
40 mg. The dose mainly used in these studies for 1 and 2 years' treatment was 40 mg 
daily and 20 mg daily for 5 years. Treatment beyond 5 years, however, is not 
recommended as 10 years of tamoxifen has not yet shown net clinical benefit over 5 
years of treatment because of the development of drug resistance and adverse side 
effects 
64-66
. In the postmenopausal setting, a switch to AIs for 2 to 3 years after 5 years 
of tamoxifen has proven to be of additional benefit 
67
.  
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1.3.1.2 Efficacy of tamoxifen 
 
In ER positive disease, tamoxifen improves disease-free survival as well as overall 
survival unconditional of other adjuvant therapies
15, 16, 44
. Tamoxifen has as well been 
shown to reduce the risk of breast cancer in women at high risk of developing breast 
cancer 
65
. The efficacy of tamoxifen treatment has repeatedly been reported in the Early 
Breast Cancer Trialists' Collaborative Group (EBCTCG) overviews, and in a recent 
meta-analysis from 20 trials and 20,000 patients, tamoxifen reduces the rate of 
recurrence by 50% the first 5 years and 30% for up to 10 years.
44
 Death rates are 
reduced by one third the first 15 years. The benefit of tamoxifen has been shown to be 
independent of factors, such as progesterone receptor (PR) status, age or nodal status. 
Interestingly, the efficacy of tamoxifen is independent of whether chemotherapy was 
given or not. Even for weakly positive ER, there is a substantial benefit of tamoxifen 
treatment and has only a marginally better effect in disease with much higher ER 
content
44, 68
 . In ER-negative disease, there is no benefit from tamoxifen. 
 
1.3.2 Aromatase inhibitors 
 
Newer endocrine therapies, such as aromatase inhibitors (AI), have shown to be more 
beneficial in regard to recurrence-free survival than tamoxifen in postmenopausal 
women. AIs inhibit the estrogen synthesis from androgens in the postmenopausal 
endocrine milieu. AIs are however not recommended for premenopausal women unless 
combined with ovarian ablative (OA) treatment. Recently, trials have been designed to 
assess whether AIs are superior to tamoxifen in premenopausal women. So far, there 
seems to be no additional benefit of AIs compared to tamoxifen in terms of survival, 
but there are substantially more side effects from AIs 
69
. 
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1.3.3 Ovarian suppression 
 
Apart from surgery, ovarian suppression is the oldest therapy still in use for breast 
cancer. Ever since Beatson's report more than a century ago, the association between 
the hormonal action of the ovaries and the proliferation of breast cells has been known 
35
. Fifty years later, the first randomised trials on ovarian ablative (OA) treatment were 
launched, and, consequently, the benefit of suppression therapy was established by the 
EBCTCG 
16, 70
. It is clear that OS improves survival in premenopausal women with 
early breast cancer 
8
. Treatment-induced OA, whether by endocrine- or chemotherapy, 
radiation or surgery, results in increased disease-free survival and overall survival in 
premenopausal endocrine-responsive breast cancer. Results from trials using LHRH 
agonists in the adjuvant setting have indicated significant benefit in terms of prolonged 
disease-free survival and improved survival with 2 years of treatment, regardless of 
other systemic treatment. Overview data on the use of LHRH agonists have shown that 
LHRH agonists have efficacy similar as cytotoxic chemotherapy. Furthermore, the 
addition of LHRH agonist to cytotoxic chemotherapy, without tamoxifen, significantly 
reduces the risk of recurrence. There is however no therapeutic benefit from 
combination endocrine therapy versus tamoxifen or goserelin alone in women treated 
with cytotoxic chemotherapy 
8
. Still, there are some unanswered questions regarding 
the role of OS. Among them is OS's potential added value to tamoxifen in the adjuvant 
setting for premenopausal women. The optimal timing and duration of OS treatment 
with LHRH agonist are yet to be defined. In addition, it is uncertain whether LHRH 
agonists have a role among those not achieving amenorrhea during cytotoxic 
chemotherapy 
70
. 
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1.3.3.1 LHRH agonists 
 
A LHRH agonist is a synthetic peptide that interacts with the luteinizing hormone-
releasing hormone receptor to elicit its biologic response, the release of the pituitary 
hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH) 
71
. 
Goserelin (Zoladex®) is a synthetic analogue of LHRH which binds to the LHRH 
receptor cells in the pituitary gland, thus leading to a short period of increased 
production of LH and production of the sex hormones testosterone and estrogen (Figure 
3-4). After about 3 weeks, a profound decrease in FSH and LH secretion results 
through receptor downregulation. In women this results in severe hypoestrogenaemia, 
but the hypogonadal state is reversible 
72, 73
 . The recommended dose of goserelin for 
premenopausal breast cancer is 3.6 mg every 28 days subcutaneously for 2-3 years, as 
that has been the dose and duration used in most studies 
74-79
. 
 
 
Figure 3. Schematic diagram of the gonadal-pituitary axis in women 
 
 12 
 
Figure 4. 
1.3.4 Long-term side effects of adjuvant endocrine treatment 
 
1.3.4.1 Side effects of tamoxifen 
 
As toxicity is low and side effects generally well tolerated, tamoxifen has been widely 
used for the past decades. The most common side effects are vasomotor symptoms, 
such as sweating and hot flushes; although undesirable, they are not serious 
80-82
. Life-
threatening and serious side effects are few but include increased risk of uterine cancer 
and thromboembolic events. The risk of uterine cancer is considerable, but highly age-
dependent, with risk low in younger women but increasing with age 
44
. The risk of 
thromboembolic event with a fatal outcome is also low among younger women 
83
. 
There is not a significantly increased risk of cerebral stroke or cardiac mortality among 
women treated with tamoxifen. Overall, tamoxifen has not been shown to increase 
mortality among patients without recurrence 
84
. In a recent overview, there is 3% risk of 
dying from other causes than breast cancer in the age group 45 to 54 years 
44
. Among 
premenopausal women, tamoxifen does not adversely affect sexual function 
85
. 
Likewise, anxiety and depression have not been significantly increased. However, 
vaginal discharge and irregular menses are more frequent among women treated with 
tamoxifen 
51, 86
. 
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1.3.4.2 Therapy-induced ovarian failure 
 
Premature ovarian failure (POF) and infertility is a frequent long-term result of 
cytotoxic chemotherapy in young women with breast cancer 
74, 87-91
. The risk of ovarian 
failure is highly correlated to a woman’s age, type of drug, dosage and duration 87, 91-96. 
The rates of chemotherapy-related amenorrhea vary from 20% to 80%. In most studies, 
the majority of women over 40 years of age become amenorrheic 
97
. The ovarian 
damage resulting from chemotherapy is not an “all or none“ phenomenon and can 
present as irregular menses, amenorrhea or infertility. Cytotoxic chemotherapy reduces 
the number and quality of oocytes in the ovaries, i.e., the ovarian reserve 
92, 93, 98-101
. 
Younger women require more chemotherapy to develop gonadal failure, which is 
probably related to the higher number of oocyte reserves in the ovaries, compared to 
women over 40 years. Older premenopausal women require shorter therapy for 
induction of amenorrhea than younger women and are more likely to develop 
permanent ovarian failure 
90, 102
. Alkylating drugs, such as cyclophosphamide, mostly 
used in combination therapies, are known to be highly toxic to the gonads. The 
cumulative cyclophosphamide dose is a strong predictive factor of chemotherapy-
induced amenorrhea in young cancer patients. Ovarian failure, induced by alkylating 
agents, is however not cell-cycle specific and rates vary mostly dependent on age. 
Amenorrhea from cyclophosphamide therapy in younger women may vary from 18% 
to 61%, whereas the rates range from 61% to 97% in older women 
87, 97,90, 102
. The well-
studied CMF chemotherapy in breast cancer is associated with a high risk of ovarian 
failure, but is also highly dependent on age 
74, 87, 103
. Newer and more beneficial 
anthracycline-based regimens, with or without taxanes have not been shown to be more 
toxic to the ovaries (Table 2) 
90, 94, 102, 104
. This is probably due to the lower cumulative 
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doses of anthracycline as well as cyclophosphamide in the taxane combination 
regimens. The addition of anti-HER-2 drugs, such as trastuzumab, are unlikely to affect 
fertility in the long term, but need to be studied. 
 
 
 
Table 2. Incidence of chemotherapy-induced amenorrhea by chemotherapy regimen 
and age 
CMF: cyclophosphamide, methotrexate, and 5-fluorouracil, FEC: 5-fluorouracil, epirubicin and 
cyclophosphamide; FAC: 5-fluorouracil, doxorubicin and cyclophosphamide, AC: doxorubicin and 
cyclophosphamide, ACD: doxorubicin, cyclophosphamide and docetaxel, ACT: doxorubicin, 
cyclophosphamide and paclitaxel, AC+TD: doxorubicin, cyclophosphamide and paclitaxel or docetaxel. 
 
 
1.3.4.3 Protective effect of LHRH agonists on the ovaries 
 
Adjuvant cytotoxic chemotherapy is often recommended for premenopausal patients on 
grounds of young age and higher risk for recurrence or metastatic disease. For the last 
decades, it has been a steady trend to postpone the first childbirth, which is presently in 
the late twenties, and it has become quite common for women over the age of 40 to 
consider pregnancy. Pregnancies after breast cancer do not adversely affect the 
prognosis and should in general not be discouraged 
110-113
. Although assisted fertility 
techniques have constantly been improving for the last decades, the need for ovarian 
protective therapies and prophylactic measures to prevent infertility is apparent. Since 
2006, the American Society of Clinical Oncology (ASCO) recommends that 
oncologists should address the possibility of infertility and take measures to protect 
fertility 
114
. Fertility consultation and treatment by cryopreservation of fertilized ova or 
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ovarian tissue can be offered to some of these patients, but this approach is not feasible 
for all, due to factors such as cancer treatment delay and cost. Some of the fertility 
techniques are still experimental and do not restore hormone production for a longer 
duration. Ovarian protection by endocrine manipulation could therefore render an 
important therapeutic option in the prevention of POF in young women with malignant 
disease, where adjuvant cytotoxic chemotherapy is recommended. The mechanism of 
possible LHRH agonist protective effect on the ovaries is not known but several 
hypotheses have been generated. One is that by gonadotropin suppression follicles are 
put in a resting state and thus are not as vulnerable to damage 
115
. Another mechanism 
might be a decrease of utero-ovarian perfusion 
116, 117
. Up-regulation of intra-gonadal 
anti-apoptotic molecules or protection of germline stem cells has been suggested as 
well 
118
. Reports on this effect have mostly been non-randomised, retrospective, some 
made with historic controls 
115, 116, 119-124
. There have been few prospective randomised 
trials of high quality, designed to examine the protective effects from LHRH agonists in 
combination with chemotherapy. Reports from these trials show a wide variety of 
results and are not conclusive 
123, 125-128
. 
 
1.3.4.4 Bone mineral density 
 
The skeleton undergoes constant remodelling throughout adult life. Estrogen receptors 
are present in bone, and estrogen plays a central role in the maintenance of bone. 
Estrogen stimulates osteoblasts, which in turn impair osteoclast activity and lead to 
decreased bone resorption 
129
. Estrogen seems to be involved as well in remodelling 
bone by directly affecting osteoclast apoptosis, leading to increased bone resorption 
130
. 
In premenopausal women these estrogenic effects act in delicate balance to define bone 
strength. However, when endogenous estrogen decreases dramatically after menopause, 
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bone resorption increases in proportion to bone formation, resulting in less bone 
strength 
131
. Bone strength reflects bone mineral density (BMD) and bone quality. At a 
young age gonadal hormones act to increase bone mass, and this reaches a peak before 
age 30 
132
. Changes in hormonal balance induce bone metabolism disturbances and 
increase bone formation as well as bone resorption. Measurements of bone quality are 
not easily assessed, and BMD is generally used as a proxy for estimating bone strength. 
BMD is determined largely by genetic factors, hormonal status, body composition and 
muscle strength. In addition, lifestyle and environmental factors, such as exercise, 
smoking, vitamin-D, calcium intake and medication influence BMD 
133
. Bone 
metabolism is highly affected by changes in ovarian function, and treatment with 
estrogen has been shown to prevent menopause-induced bone loss 
134-136
. After the 
onset of menopause, decrease in estrogen levels is associated with an annual average 
loss of bone of 1-3% 
137, 138
. The bone loss is accelerated in the first menopausal years 
but continues at a slower rate throughout life. Early menopause is one of the strongest 
predictors of osteoporosis 
133
. Estrogen-sensitive changes in BMD are most rapidly 
seen in the lumbar spine and the hip, where osteoporotic fractures are also frequent and 
cause considerable morbidity and health economical consequences 
138
. Osteoporosis 
can be classified as either primary or secondary. In women, primary osteoporosis often 
follows menopause, and secondary osteoporosis may be result of medication or disease. 
Current clinical guidelines recommend proactive monitoring and intervention for 
osteoporosis among women treated for breast cancer 
139, 140
. More attention to 
conditions associated with secondary osteoporosis is needed, and measures to protect 
skeletal health are recommended 
140
. Treatment with bisphosphonates has shown to be 
effective in preventing decrease in BMD from ovarian ablative therapy and should be 
considered when appropriate 
141-144
. Therapy-induced bone loss is a well known long-
term effect of OA 
145-148
. Women developing chemotherapy-induced amenorrhea 
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undergo accelerated loss of bone mass, compared with women maintaining their 
ovarian function
142, 147, 148
. The effect of LHRH agonists on the ovaries is reversible, but 
there have been few reports on bone mass changes after stopped treatment. In 
postmenopausal women, tamoxifen has well-studied agonistic oestrogenic effects on 
bone 
47, 53, 54, 149
. In contrast, tamoxifen induces bone loss in premenopausal women 
although the exact mechanism remains unclear 
52, 53, 147
. In addition to LHRH-agonists 
tamoxifen results in less changes in BMD 
52
 
69
. Hence, tamoxifen seems to modify 
somewhat the demineralising effect of LHRH-agonist in bone. The possible role of AI 
treatment in combination with LHRH agonist is not clear, but the addition of AIs is 
likely to exaggerate the bone effects. At present, there is limited data from the adjuvant 
setting, but AIs alone have shown a marked effect on bone metabolism
67, 69, 143, 150, 151
. 
Treatment with bisphosphonates has been shown to effectively reduce therapy-induced 
bone loss
141, 152, 153
. In addition, there is data from studies on bisphosphonate zoledronic 
acid, which effectively counteracts the demineralising effects from goserelin, as well as 
improves disease-free survival 
69, 143
. 
 
1.3.4.5 Bone turnover markers  
 
In spite of BMD being the standard for assessing bone mass changes, it does not 
provide information about the rate of bone turnover. Markers of bone formation and 
bone resorption can, in addition to BMD, give preciser information on bone quality and 
better predict fracture risk
154
. Changes in markers of bone turnover reflect changes in 
skeletal metabolism. Alkaline phosphatase (ALP) plays an important role in bone 
formation and mineralisation. ALP is produced in various tissues such as liver, bone, 
intestine, spleen, kidney and placenta. Around 50% of ALP in serum originates from 
bone. Bone-specific ALP isoenzyme assay can be used to detect bone ALP. 
Osteocalcin (OC) is a hydroxyapatite-binding protein synthesized by osteoblasts, 
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odontoblasts and hypertrophic chondrocytes. Osteocalcin is a well-established marker 
of bone formation but lacks both sensitivity and specificity 
155
. OC is considered a 
specific marker of osteoblast function. Newer markers, such as pyridinoline, cross-
linked amino-terminal telopeptide of type I collagen (PINP) and C-terminal telopeptide 
(CTX), which is a bone resorption marker, increase the predictability of bone turnover 
134, 155
.These markers are derived from collagen type I and can be measured by specific 
immunoassays. Bone turnover is easily affected by several factors, such as age, disease, 
drugs, recent fracture, circadian, menstrual or exercise effects, which need to be 
considered in clinical interpretation 
156-158
. Bone markers are known to increase after 
the menopause, whereas bone protecting therapies, such as with calcium and 
bisphosphonates, have been shown to decrease levels of BTM 
134-136, 141, 154
. High bone 
turnover has been associated as well with malignant bone disease and negative 
prognosis in metastatic disease 
159
. Up to now, however, there is no consensus on the 
clinical use of bone markers. 
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2 AIMS OF THE STUDY 
 
To evaluate the efficacy and some long-term side effects of adjuvant endocrine 
treatment in premenopausal breast cancer by testing the following hypotheses: 
 
I: Adjuvant tamoxifen in combination with LHRH agonist is superior to tamoxifen 
alone, LHRH agonist alone or no endocrine therapy in regard to recurrence-free 
survival after radical surgery 
 
II: The efficacy of the different endocrine therapies is dependent on the levels of 
estrogen receptor content. 
 
III: LHRH agonist treatment have a protective effect on ovarian function in adjuvant 
cytotoxic chemotherapy. 
 
IV: Treatment with LHRH agonist alone significantly increases bone loss. 
 
V: LHRH agonist-induced bone loss is reversible after cessation of therapy and can be 
reduced by concomitant tamoxifen therapy. 
 
VI: Biochemical markers of bone turnover may be useful for early detection of patients 
at risk of accelerated bone loss, as well as for monitoring and early intervention in 
prevention of osteoporotic fractures. 
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3 PATIENTS AND METHODS 
 
3.1 PATIENT COHORT IN STUDIES I-IV 
 
3.1.1 The Zoladex in Premenopausal Patients (ZIPP) trial 
 
The ZIPP trial was a collaboration between four research groups: 1) Stockholm Breast 
Cancer Group, 2) South East (S-E) Sweden Breast Cancer Study Group, 3) Cancer 
Research UK and UCL Cancer Trials Centre (CRC), United Kingdom (UK) and 4) 
Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO), Italy. The study 
was designed to determine whether the addition of goserelin and/or tamoxifen to 
adjuvant therapy provided benefit for premenopausal women with early breast cancer
77, 
160
. The inclusion criteria were women, premenopausal or under 50 years of age, with 
stage I or II breast cancer, unconditional of ER status. Surgery of the breast/axilla and 
radiotherapy was according to local routines, as well as adjuvant chemotherapy. The 
protocol recommended CMF chemotherapy, but some centres used a regimen of 5-
fluorouracil, epirubicin and cyclophosphamide (FEC). Initially, patients were to enter a 
2 x 2 factorial randomisation. However, randomisation was not strictly factorial at all 
participating study sites. Randomisation was strictly 2 x 2 factorial throughout the 
study period only in the Stockholm and Italian centres. In the UK centres patients were 
initially entered into 2 x 2 factorial randomisation, but as the study proceeded, 
tamoxifen randomisation became optional and tamoxifen in 20 mg daily doses was 
allowed electively. In S-E Sweden patients were initially entered into a 2 x 2 
randomisation to tamoxifen 40 mg daily, but later in the study all patients were given 
tamoxifen. The inconsistencies in the study design are mainly due to the uncertainty of 
the role of tamoxifen in the premenopausal setting at the time of the study planning. 
Goserelin was administered by subcutaneous injection of 3.6 mg every 28 days for 2 
years at all sites
77
. 
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3.1.2 The Stockholm cohort of the ZIPP trial (Papers I-IV) 
 
In Stockholm all patients were included in a 2 by 2 factorial randomisation for 
goserelin (3.6 mg subcutaneously every 28 days), tamoxifen (40 mg daily), a 
combination of goserelin and tamoxifen or no endocrine therapy for 2 years. Node-
positive women were allocated to adjuvant CMF chemotherapy (six cycles of 
cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and 5-fluorouracil 600 mg/m2 
intravenously administered on days 1 and 8, every 28 days), in addition to endocrine 
therapy. Patients with four or more positive lymph nodes received additional loco-
regional radiotherapy, including the chest wall, axillary and supraclavicular lymph 
nodes, 46 Gy for 4.5 weeks (Figure 5). Endocrine treatment was given concurrently 
with chemotherapy. The randomisation was stratified in three groups, based on nodal 
status and use of other adjuvant therapies: node negative patients receiving no adjuvant 
chemotherapy, patients with one to three positive lymph nodes who received 
chemotherapy and patients with four or more positive lymph nodes who received both 
chemotherapy and loco-regional radiotherapy. Randomisation was carried out by 
telephone to a central office where the patient identifiers were recorded before the 
allocated treatment was revealed to the responsible physician. Treatment allocation was 
based on balanced lists, using the permuted block technique. The inclusion criteria were 
invasive breast cancer ≥ 10 mm, premenopausal menstrual status (defined as last 
menstruation ≤ 6 months earlier), primary surgery consisting of a mastectomy or a 
wedge resection plus axillary node dissection and no clinical evidence of distant 
metastases. The exclusion criteria were inoperable breast cancer, previous radiotherapy 
or neo-adjuvant chemotherapy and previous or concurrent endocrine therapy. 
Patients from the Stockholm cohort were recruited to several studies, designed and 
conducted by the Stockholm Breast Cancer Study Group: 
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I: Study of the efficacy of and interaction between LHRH agonist and tamoxifen 
II: Study of ovarian protection from LHRH agonist treatment 
III: Study of bone mineral effects 
IV: Study of bone turnover markers 
V: Study of endocrine side effects (Quality-of-life) 
VI: Study of chemo- and/or endocrine therapy's effects on sexuality 
VII: Study of factors influencing return to work after adjuvant treatment 
Studies V-VII have been described and reported separately 
51, 85, 161
. Studies I-IV are 
included in this thesis. 
 
 
Figure 5. Study design and recruitment in studies I - IV. 
 
All patients with breast-conserving surgery were assigned radiotherapy (RT) to the 
breast, 50 Gy's in 5 weeks. pT: pathological tumour size in millimetres, pN: 
pathological nodal status, CMF: cyclophosphamide, methotrexate and 5-fluorouracil, 
Tam: tamoxifen 
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3.1.3 Paper I 
 
A total of 927 women in Stockholm were recruited to the study from May 31, 1990, to 
January 8, 1997. Of the 927 recruited women, 234 were randomised to the control (C) 
arm, 231 were randomised to receive goserelin (G), 231 to tamoxifen (T) and 231 to 
goserelin plus tamoxifen (GT) therapy. One woman was incorrectly randomised twice 
and one woman was diagnosed with recurrent disease at the date of randomisation. The 
remaining 925 women were included in the analysis (Figure 5). The common end of 
follow-up was January 1, 2006. 
 
3.1.3.1 Efficacy 
 
Time to event was calculated as time from the date of randomisation to the date of 
disease recurrence, contralateral breast cancer, other cancer or death without a reported 
recurrence, whichever came first. Time for alive and event-free patients was calculated 
from the date of randomisation to the common end-date for follow-up, December 31, 
2005. The Kaplan–Meier technique was used to estimate failure probability, and the log 
rank test was used to test for difference in time to event between treatment groups. 
Hazard rate ratios and 95% confidence intervals were estimated using proportional 
hazards regression. When assessing the main treatment effect of tamoxifen or goserelin, 
the other treatment was used as control. Test for interactions was performed by 
inclusion of product terms in the regression models. We also analysed the effect of 
treatment on time to first recurrence according to level of ER content. Data on ER 
content were available on 793 patients (86%). Interaction between treatments and ER 
content were further investigated graphically by the use of Subpopulation Treatment 
Effect Pattern Plots (STEPP). The STEPP analysis was performed using the program 
stepp_tail, implemented in the statistical software Stata. 
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3.1.3.2 Hormone receptor content 
 
All hormone receptor analyses on tumour samples were performed at a single 
laboratory, which participated in repeated control studies for receptor determination, 
using the same technique. The ER content was determined by isoelectric focusing on 
polyacrylamide gel. The receptor values were normalised to DNA content as measured 
by Burton and expressed as the binding capacity of estradiol in fmol/µg DNA 
28
. 
Tumours with a receptor content equal to or more than 0.05 fmol/µg DNA were 
classified as ER-positive, whereas tumours with estrogen content less than 0.05 
fmol/µg DNA were classified as ER-negative 
162
. We further subdivided ER-positive 
tumours into intermediate ER: 0.05–0.59 fmol/µg DNA and high-ER: ≥ 0.60 fmol/µg 
DNA. The cut-off for the two ER-positive groups was made at a level which created 
equally sized groups.  
 
3.2 PATIENT COHORT IN STUDIES II-IV 
 
The Stockholm Breast Cancer Study Group initiated sub-studies of treatment-related 
side effects in the Stockholm cohort of the trial, such as effects on ovarian function, 
bone mineral density, return to work and quality of life. Between October 1990 and 
June 1994, patients were recruited to these studies. 
 
3.3 PAPER II 
 
285 out of 408 (70%) eligible patients in the randomised trial were recruited to the 
study of ovarian function. Patients were allocated to the study before randomisation to 
the treatment arms. The reason that 123 patients were not recruited was the patient’s 
preference. Additionally 25 patients were excluded because of recurrent disease. The 
remaining 260 patients were included in the analyses (Figure 6).  
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Figure 6. Study design and patient flow diagram 
 
3.3.1 Instrument 
 
Self-reporting questionnaires were obtained from patients on scheduled visits to the 
outpatient clinic at baseline, 3 months, 12, 24, 30 and 36 months after randomisation. 
The questions on menses were a part of the quality-of-life questionnaire designed for 
the study of side effects 
163
. The women reported whether menses had ceased, had not 
ceased but become scanty or not ceased since the previous survey and visit to the 
outpatient clinic. The first survey was made at the time of randomisation and the period 
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since the previous survey, varied from 3 to 9 months. All analyses were performed 
according to the intention-to-treat principle. In analysing each time point, menses self-
reported as regular or irregular were deemed as having menses, whereas women 
reporting absence of menses were assessed as being amenorrheic. Fisher’s exact test 
was used to assess differences between the treatment groups. 
 
3.4 PAPERS III-IV 
 
Between October 1990 and June 1994, patients at the Department of Oncology, 
Karolinska University Hospital Södersjukhuset in Stockholm were recruited to the 
study of bone effects. Only patients from the strata not receiving chemotherapy were 
eligible for the study on BMD and bone markers. A total of 89 (81% of eligible patients 
at the two participating hospitals during the period of entry) node-negative patients 
from the four randomised groups were recruited to the bone mineral study. Of the 
eligible women, 27 patients were assigned to groups either receiving tamoxifen or 
tamoxifen plus goserelin; 26 patients were assigned to receive goserelin alone, and 30 
patients were assigned to the control group (Figure 5).  
 
3.4.1 Bone mineral density study (Paper III) 
 
Women with recurrent or metastatic disease were withdrawn from further bone mineral 
examinations. Data for 23 patients were unavailable after 12 months. Of these, 3 
patients died, 6 patients had missing data because of their preference, and 14 patients 
had missing data because of administrative errors. Complete data on all four 
measurements as defined in the protocol were available for 53 patients. The mean 
difference in BMD change between examinations at 24 months and baseline and within 
the treatment groups was tested by the paired t-test Differences in BMD change 
between treatment groups were estimated by multiple linear regression, controlling for 
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baseline values. Analyses were made according to the intention-to-treat principle and 
included women with at least three measurements of BMD available. 
 
3.4.2 Bone Densitometry (Papers III-IV) 
 
Bone density measurement was made before initiation of treatment and at 12 months, 
24 months, and 36 months post-initiation (i.e., the last examination was made 1 year 
after treatment finished). Total body bone mass (TBBD) was measured by dual-energy 
x-ray absorptiometry, using a Lunar DPX-L device (Lunar Corporation, Madison, WI). 
The precision of the technique is 1%, and the accuracy is 10%. BMD of the lumbar 
spine (L2 to L4) was measured at baseline for the patients as well for validation of the 
equipment used. An experienced investigator blinded to the individual patients' 
identities analyzed the scans. All measurements were made with the same equipment 
and evaluation procedures. 
 
3.4.3 Bone marker assays (Paper IV) 
 
Blood sampling was performed on the planned visits to the out-patient clinic at baseline 
and every three months up to one year after stopped treatment. A total of 110 patients 
recruited to the examinations of bone markers were recruited to the study. Blood 
samples were collected at 6-month interval up to 36 months. All blood samples were 
drawn and stored at -70°C at the same centre (hospital, out-patient clinic). All blood 
analyses were performed at one laboratory, with the same equipment and technique. Of 
the 82 patients where blood samples were available at baseline, 17 were excluded from 
analysis (three because of metastatic or recurrent disease, two because of death and 
twelve because of patient preference). Of the remaining 65 patients, analysis included a 
total of 50 patients, where bone marker assays were available at baseline and 6 months. 
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BMD examinations were done at baseline and 6 months; in addition, bone marker 
assays were available for 40 patients.  
The biochemical bone turnover markers osteocalcin (OC), pyridinoline cross-linked 
amino terminal telopeptide of type I collagen (PINP) and C-terminal telopeptide (CTX) 
were measured. The OC measurements were made with Elecsys(R) 1010/2010 System 
Osteocalcin Immunoassay. The assay uses 2 monoclonal antibodies against the N-
MID-fragment and N-terminal fragment of the osteocalcin molecule. The method is 
non-dependent on the unstable C-terminal fragment. The sensitivity of the assay is 50 
µg/L. The PINP analyses were made by immunoassay technique, using Roche Elecsys 
total PINP test with a sensitivity of 5 µg/L, and β –CTX was measured with Elecsys β-
CrossLaps/serum assay. The assay uses 2 monoclonal antibodies against a cross-linked 
isomerised type I collagen fragment and has a sensitivity of 0.05 ng/ml. Values for OC, 
PINP and CTX are expressed in ng/mL. The intra- and interassay coefficient of 
variation (CV) was 2.0% and 4% for OC, 1.7% and 4.4% for PINP and 2.5% and 3.5% 
for CTX. The mean ratio (6 months/baseline) was calculated as the mean paired 
difference of the log-transformed variables and was tested using the t-test. The log-
transformed differences were then back-transformed, where the antilog of the mean 
differences is an estimate of the geometric mean of the ratio of the variables. Results 
are presented as ratios together with 95% confidence intervals. Association between 
BMD and the bone markers OC, PINP and CTX was assessed by using the Spearman 
rank correlation coefficient. Confidence intervals for the correlation coefficients are 
based on Fisher's transformation. 
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4 RESULTS 
 
4.1 PAPER I 
 
The treatment groups were similar in regard to clinical and histopathological 
characteristics, as seen in Table 3. 
 
 
Table 3. Patients characteristics by allocated treatment 
 
After a median follow-up time of 12.3 years, 166 women presented with loco-regional 
recurrence as a first event, 159 had distant metastases, 54 had contra-lateral breast 
cancer, 50 women were diagnosed with other cancers, and there were 6 deaths as first 
event. The overall number of deaths from breast cancer was 225, and there were 26 
non-breast cancer deaths. The total number of first events was 435. There were 128 
(55%) first events in the C group, 98 (42%) in G treated, 101 (44%) in T treated and 
108 (47%) in the GT group (Table 4). 
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Table 4. Proportion of the type of first event in the different treatment groups 
 
Three main sets of analyses were carried out: first the overall effect of endocrine 
therapy versus no endocrine therapy; second, the effect of goserelin with or without 
tamoxifen and, finally, the effect of tamoxifen with or without goserelin. 
1. Compared to the controls, endocrine treatment with either goserelin alone or 
combined with tamoxifen or endocrine treatment with tamoxifen alone reduced 
the risk of first recurrence by 32% (CI, 0.52–0.89), 24% (CI, 0.59–0.98) and 
27% (CI, 0.56–0.94), respectively (P = 0.021).  
2. Goserelin treatment reduced the risk of first recurrence by 16% (CI, 0.68–1.02). 
There was no additional beneficial effect of goserelin with tamoxifen, but in the 
absence of tamoxifen, first recurrence was reduced by 32% (CI, 0.53–0.89).  
3. The main effect of tamoxifen was not statistically significant (HR: 0.89, CI, 
0.74–1.08), but when examined separately for those not treated with goserelin, 
there was a 27% benefit from tamoxifen (CI, 0.56–0.95). A test for interaction 
between goserelin and tamoxifen was statistically significant (p = 0.025) 
(Figure 7). 
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Figure 7. First event according to treatment groups.  
 
C: controls, G: goserelin, T: tamoxifen, TG: tamoxifen and goserelin, G-: without 
goserelin, G+: with goserelin, T-: without tamoxifen, T+: with tamoxifen 
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When we examined the treatment effect for different levels of ER content, there was an 
overall effect of goserelin in the high-ER group (HR: 0.71, CI, 0.50–0.99, P = 0.044) 
and a trend towards greater risk reduction with increasing levels of ER content. The 
greatest risk reduction from goserelin treatment in the group with high ER was 
observed among those not receiving tamoxifen (HR: 0.52, CI, 0.32–0.84, P = 0.007). 
The main effect of tamoxifen in the high-ER group was not significant (HR: 0.85, CI, 
0.61–1.18). Neither was there a significant risk reduction for tamoxifen alone (HR: 
0.68, CI, 0.44–1.05, P = 0.081). For the intermediate ER group, there was no main 
effect from either goserelin (HR: 0.80, CI, 0.57–1.14) or tamoxifen (HR: 0.97, CI, 
0.68–1.38). Finally, among those classified as ER negative, there was no main effect 
from goserelin (HR: 1.25, CI, 0.85–1.82), tamoxifen (HR: 0.85, CI, 0.59 to 1.24) or 
combined goserelin and tamoxifen (HR: 1.03, CI, 0.63–1.67). In the intermediate and 
ER-negative groups, the treatment effects of goserelin and tamoxifen did not modify 
each other (Fig. 8). 
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Figure 8. Subpopulation treatment effect pattern plot at different ER levels.  
 
The curves show hazard ratios on a logarithmic scale for treatment interactions.  
Circles represent the treatment effect (plotted at the category mean) in the ER 
categories: < 0.05, 0.05–0.59 and ≥ 0.60 fmol/µg DNA. 
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4.2 PAPER II 
 
4.2.1 Women treated with CMF chemotherapy 
 
At baseline, 6% (7/119) women reported absence of menses, which was in accordance 
with inclusion criteria, as premenopausal status was defined as the last menses within 
less than 6 months. At 3 months, 50% (13/26) of the women in the C group reported 
amenorrhea. For women in the T group, the figure was 73% (19/26). Women in G or 
GT groups, reported amenorrhea in 93–94% (26/28 and 34/36 respectively) of cases. At 
24 months, i.e., after 2 years of endocrine treatment, 85% (17/20) of the controls, 95% 
(19/20) of the T group, 97% (29/30) of the GT and 92% (22/24) of the G group were 
amenorrheic. At this time point, there was no statistically significant difference in 
amenorrhea for goserelin-treated patients, compared to all other treatment groups (P = 
1.00). Six months after cessation of endocrine treatment, the proportion of amenorrheic 
women continued to increase to 94% (16/17) for the controls, was 87% (20/23) for the 
T group, unchanged at 92% (24/26) for the GT group, but only 67% (14/21) of the 
women treated with goserelin reported absence of menses at this time point. At 36 
months, i.e., 1 year after stopped endocrine treatment, the proportion of amenorrheic 
women in the control group was 90% (18/20), 87% (20/23) for the T group, 93% 
(27/29) for the GT group but had decreased to 64% (14/22) for the G group. The 
increase in the proportion of menstruating women in the G group was statistically 
significant, compared to all other groups where menses were unchanged or decreasing 
between 24 and 36 months (P = 0.006) (Fig. 9).  
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4.2.2 Women not treated with CMF chemotherapy 
 
All randomized patients reported having menses at baseline. At 3 months, 9% (3/34) of 
the controls, 21% (6/29) of the T group, 86% (31/36) of the GT group and 97% (32/33) 
of the G group were amenorrheic. At 2 years after randomization, 13% (4/31) of the 
controls, 21% (5/24) of the T-group, 69% (22/32) of GT-group and 82% (23/28) of the 
G-group reported amenorrhea. Six months after completed endocrine treatment, 17% 
(5/29) of the controls, 12% (3/24) of the T group, 28% (8/29) of the GT group and 37% 
(10/27) of the G group were amenorrheic. At 36 months, i.e., 1 year after completed 
endocrine treatment, 20% (6/30 and 5/25 respectively) of the controls and T group, 
32% (10/31) of the GT group and 41% (12/29) of the G group were amenorrheic. At 36 
months, i.e., 1 year after stopped endocrine therapy, there was no statistically 
significant difference in the menstrual status of women treated with goserelin, 
compared to all other treatment groups (P = 0.15). 
 
Figure 9. Ovarian function according to treatment. Percentage of CMF treated women 
menstruating at different time points 
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4.3 PAPER III 
 
During the first 2 years, all three endocrine treatment groups showed a significant 
decrease in BMD, and the greatest changes in all measurements were seen in patients 
allocated to goserelin treatment. The groups receiving tamoxifen alone or tamoxifen 
plus goserelin showed a less but continuous decline in BMD. For patients allocated to 
the control group, no significant change in BMD was found. The G group showed an 
average change from baseline in BMD (in grams per centimetres squared) of - 0.057 (P 
< 0 .001). In the TG group the change was -0.015 (P = 0 .02), and in the T group the 
change was -0.018 (P < 0.001). In the group receiving no endocrine treatment, the 
change was -0.002 (P = 0.76). These absolute changes correspond to decreases in BMD 
of 5.0%, 1.4%, 1.5%, and 0.3% for the G group, TG group, T group, and control group, 
respectively. Of the endocrine-treated groups, only the G group significantly differed in 
mean change in BMD at 2 years, compared to the control group (-0.058 g/cm2; 95% CI, 
-0.078 to -0.039; P < 0.001). At 3 years (1 year after cessation of treatment), the G 
group alone showed a partial recovery from bone loss, with a change of 0.017 (P = 
0.02). This corresponds to an increase in BMD of approximately 1.5%. None of the 
other groups showed significant changes in BMD during this period. Changes in BMD 
are presented in Figure 10. Baseline measurements of BMD of the lumbar spine 
showed a correlation with TBBD (r = 0.8). 
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Figure 10. Change in bone mineral density in the different treatment groups 
 
Mean change in BMD (g/cm
2
) in different treatment groups from baseline up to 3 years 
of treatment for 53 patients. C: control, T: tamoxifen, TG: tamoxifen plus goserelin, G: 
goserelin  
 
4.4 PAPER IV 
 
Among women treated with goserelin (G), there was a statistically significant elevation 
of all bone markers at 6 months. The mean increase in OC was 57% (CI, 1.31-1.89, p < 
0.001); PINP increased by 65% (CI, 1.29-2.11, p = 0.001), and there was a 98% 
increase in CTX (CI, 1.55-2.53, p < 0.001). Among women treated with goserelin in 
combination with tamoxifen (TG), there was a 5% decrease in OC (CI, 0.83-1.08, p = 
0.35), a 13% decrease in PINP (CI, 0.75-1.02, p = 0.087), and a 10% increase in CTX 
(CI, 0.84-1.42; p = 0.45). In women treated with tamoxifen alone (T), OC decreased by 
13% (CI, 0.54-1.40, P = 0.52), PINP by 13% (CI, 0.54-1.40, P = 0.52), and there was 
an increase in CTX of 4% (CI, 0.83-1.30, P = 0.71). Among the control (C) group of 
patients, OC decreased by 3% (CI, 0.83-1.12, P = 0.64), PINP by 22% (CI, 0.67-0.91, P 
= 0.003), and there was a 15% increase in CTX (CI, 0.98-1.36, P = 0.076). Among the 
40 patients where BMD examinations were available at baseline and at 6 months, there 
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was on average a 4% decrease in total body bone mass among G-treated patients (CI, 
0.95-0.97, P < 0.001), a 2% decline among TG-treated patient as well as those treated 
with T alone (CI, 0.97-0.99, P < 0.001 and 0.97-1.00, P = 0.012, respectively). There 
was no statistically significant change in BMD in the C group (CI, 0.98-1.01, P = 0.86) 
(Table 4). Spearman rank correlation analysis showed that change in BMD was 
inversely correlated to change in all bone markers. After 6 months of treatment, there 
was a statistically significant association between change in BMD and OC (r = -0.51, 
CI, -0.71 to -0.23), PINP (r = -0.40, CI, -0.63 to -0.10) and CTX (r = -0.41, CI: -0.64 to 
-0.10) (Table 5). 
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Table 5. Mean blood values of bone markers and bone mineral density by allocated 
treatment. 
 
A
Mean ratio (6 months / baseline) of the paired values. 
B
Paired t-test on log-
transformed data. 
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5 DISCUSSION 
 
This thesis focuses on the efficacy as well as long-term side effects in regard to bone 
health and ovarian preservation from ovarian ablative therapy in premenopausal 
breast cancer. All results are based on the Stockholm cohort of the larger ZIPP trial.  
5.1 PAPER I:  
The Stockholm cohort was exceptional in several aspects in comparison to the main 
ZIPP trial. In our study, patients were randomly assigned to endocrine therapy by a 
strict 2 x 2 factorial design, as was initially planned for the main trial. This cohort was 
also well defined according to hormone receptor content, nodal status and whether 
chemotherapy and/or radiotherapy were given or not. In addition, our strictly 
randomised data, based on all ER measurements made in a single laboratory, were 
suited for examining the significance of ER content for predictability of endocrine 
therapy. The EBCTCG Overview group has concluded that LHRH agonists alone 
improve survival in the adjuvant setting in hormone receptor positive breast cancer 
8, 
70
. There are, however, some remaining questions regarding their optimal use. Among 
these is the uncertainty over the added value of combining tamoxifen with a LHRH 
agonist. As there is lack of data from randomised trials where LHRH agonists are 
tested against chemotherapy, with or without tamoxifen in both arms, a separate study 
of our cohort therefore seemed reasonable. Furthermore, the analyses of ER content, 
analysed at a single, highly qualified laboratory with a quantitative cytosol method, 
allowed analysis of the effect of different receptor levels on outcome. Our study 
shows that the effect of goserelin on recurrence is considerable. The most marked 
effect of goserelin is seen among those not concomitantly receiving tamoxifen. In a 
recent update of the ZIPP trial, there was also a survival benefit, not possible for us to 
examine in the Stockholm cohort because of the small sample size 
160
. Our study 
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allows formal testing of interaction that is not possible for the overall trial because of 
inconsistencies in the study design. This formal test of the interaction between 
goserelin and tamoxifen in our randomised cohort confirms what was indicated in the 
overall trial report, i.e., that tamoxifen provides no additional benefit among women 
treated with goserelin. The same is true for the opposite, where goserelin provides no 
additional benefit for those treated with tamoxifen. Tamoxifen is effective in 
extending the time to first recurrence, but only among those not receiving goserelin. 
Our results, showing no additional benefit from combined endocrine therapy, are 
consistent with Overview data 
164
. Former reports on combination endocrine therapy 
in postmenopausal adjuvant setting, such as the ATAC and ABCSG-12 trials, as well 
as the FACT trial in the metastatic setting, have also shown a lack of benefit 
69, 150, 165
. 
Interestingly, the principle of combining endocrine drugs for improved efficacy has 
therefore not been proven. Sequential endocrine therapy, on the other hand, has 
proven to be beneficial, as seen in the BIG 1-98 and MA-17 trials 
67, 166
. Survival 
analysis of the effect from different endocrine treatment overall, or in the subset of 
women developing chemotherapy-induced amenorrhea, was not possible in our study 
due to the limited cohort size. The ongoing Suppression of Ovarian Function Trial 
(SOFT) is expected to clarify the effect of combination endocrine therapy in the 
premenopausal setting more decisively. Our analysis of ER levels confirms the lack 
of effect on ER-negative women, in line with previous reports 
16, 44
. An intriguing 
finding is, however, that the effect of goserelin increases with higher ER levels, 
whereas the effect of tamoxifen is unconditional of ER content. This may be a finding 
of chance, but the data indicate a clear difference, which may be based on biological 
grounds. Goserelin, which has a stronger estrogen suppressor effect than tamoxifen, is 
potentially more effective when ER content is high. In this group, tamoxifen may not 
have sufficient effect to counteract the highly estrogenic milieu of premenopausal 
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women. The STEPP plots demonstrating this effect are, however, based on small 
subsets of patients, and the data therefore have to be interpreted conservatively. 
Among postmenopausal women earlier studies have shown a significant trend in 
reduction of recurrence rate with higher ER levels among women treated with 
tamoxifen 
167
 
27, 30, 162
. This supports the significance of stronger ER content in 
endocrine treatment where ovarian function is absent. A recent overview of pre- and 
postmenopausal patients shows unequivocal benefit of tamoxifen in all ER-positive 
categories, and the benefit is not dependent on the strength of ER content as formerly 
suggested 
15, 44
. This supports our data in regard to the predictability of a tamoxifen 
effect related to ER content. 
Quality of life aspects and long-term side effects are important factors to be taken into 
consideration when assessing improvements in adjuvant therapy. The Overview group 
earlier showed that goserelin is an option for women strongly opposed to cytotoxic 
drugs, or where chemotherapy is contraindicated 
8
. Premature menopause is highly 
probable after chemotherapy, and desire for pregnancy is not uncommon after 
completed treatment. Moreover, some women may be reluctant to risk the adverse 
effects of permanent ovarian failure, such as infertility and accelerated bone loss. In 
addition to the studies presented here, the Stockholm cohort has been studied 
extensively concerning quality of life aspects and reported in several of publications 
51, 
85, 161
. Berglund et al. have earlier shown that sexual dysfunction from goserelin was 
substantial the first 2 years but diminished over time, whereas chemotherapy-related 
symptoms were on-going at follow-up at 3 years
85
. Nystedt et al. have similarly shown 
in the same cohort that menopausal side effects from goserelin the first 2 years are 
worse than from CMF. There were no differences in side effects from goserelin and/or 
tamoxifen among those receiving CMF chemotherapy. Only patients who did not 
receive chemotherapy had various effects from endocrine treatment. Among those, 
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treatment with goserelin was worse than therapy with combined goserelin-tamoxifen or 
tamoxifen alone. Anxiety and depressive symptoms were not significantly affected by 
endocrine treatment or chemotherapy. At 3 years of follow-up, the menopausal 
symptoms from goserelin reversed, whereas physical symptoms of CMF therapy 
effects were persistent 
86
. Tolerability of goserelin in the adjuvant setting has also been 
reported by the Zoldex Early Breast Cancer Research Association (ZEBRA) with 
similar results. Side effects related to therapy-induced menopause were worse for 
goserelin, compared to CMF the first 2 years of treatment. However, one year after 
stopped treatment, side effects increased among patients treated with CMF, whereas 
side effects reversed when menses returned after goserelin treatment 
74, 168
. Sick leave 
and factors associated with returning to work after treatment were examined by 
Johnson et al. Their study showed that endocrine therapy was associated with a twofold 
increase of risk of not having returned to work after 2 years 
161
. Compliance in the 
studies described here (papers I-IV) was good in all study groups. Compliance to 
adjuvant endocrine therapy is a factor that has recently come increasingly into focus. 
Adherence to 5 years of treatment can be a challenge for patients suffering from 
menopausal symptoms, and lack of compliance translates into inferior survival rates 
169
. 
Clearly, this presents a great challenge for health professionals in regard to patient 
information as there is need for adequate follow-up and appropriate treatment of 
adverse effects. Lately, the use of selective serotonin reuptake inhibitors (SSRIs) that 
block the enzyme CYP2-D6 has been used against hot flushes, but there is concern that 
blocking the enzyme which metabolically activates tamoxifen to the potent 
antiestrogenic endoxifen reduces the benefits of the drug 
170
. Selective norepinephrine 
reuptake inhibitors (SNRIs), such as venlafaxine, may be a safer alternative. The 
genetic variants of CYP2-D6 may also influence outcome among tamoxifen treated, but 
further research is needed before a routine assessment of the enzyme is recommended. 
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A limitation of the design of the Stockholm study may be the 2 years of 40 mg/day 
tamoxifen, which was standard at the time, instead of 5 years of 20 mg/day treatment as 
currently recommended. In contrast to tamoxifen, 2 years of goserelin is still within the 
recommended treatment period of 2 to 3 years although the optimal duration of 
treatment is not yet determined. Another limitation is the concurrent use of 
chemotherapy in the trial, which may not be optimal, based on the risk of endocrine 
therapy interacting with chemotherapy and sequential treatment currently being 
recommended as standard. This concern, however, is primarily based on a single report 
by Albain et al. 
171
. In all studies presented here (Papers I-IV), randomisation 
minimized the risk of uneven distribution of such factors in the different treatment 
groups. 
 
5.2 PAPER II: 
Our study on ovarian function shows, that amenorrhea is significantly less frequent one 
year after completed treatment among patients treated with goserelin as the only 
additive endocrine therapy during chemotherapy. This suggests that goserelin has a role 
in protecting ovarian function in a cytotoxic milieu, as has been reported in a recent 
review of randomised trials by the Cochrane group. There it is concluded that the use of 
LHRH agonists seems to be effective in protecting ovaries during chemotherapy and 
should be considered in women of reproductive age receiving chemotherapy 
172
. 
Previous data have nevertheless been conflicting. Several non-randomised studies have 
shown benefit from LHRH agonist treatment 
96, 122-124, 173
. Other studies have shown no 
difference in the menses restoration rates 
119, 121, 127
. The ZORO trial by the German 
Breast Group, where goserelin prophylaxis during taxane-based chemotherapy was 
investigated, showed no protective effect from goserelin on ovaries function 
126
. In our 
study, the benefit is moderate and may be due to several effect modifiers, such as high 
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age and the timing of LHRH agonist treatment. Here, the age is rather high for a 
premenopausal population, with a mean age of 45 years. This is an age where natural 
menopause approaches, and age above 40 years is undisputedly a strong risk factor for 
permanent chemotherapy-induced amenorrhea 
174
. The timing of goserelin treatment is 
another factor, which possibly may not be optimal concerning a potential effect on 
preservation of ovarian function. Theoretically, LHRH agonist treatment should 
preferably start at least 2 weeks before initiation of chemotherapy, as an approach to 
optimising ovarian suppression in advance of cytotoxic chemotherapy effects. In our 
study, however, goserelin injections were started simultaneously with the first CMF 
course, which may be too late for achieving full effect. On the other hand, there are 
concerns of possible hazards from concomitant LHRH agonist and cytotoxic 
chemotherapy. Theoretically, there is a risk of an LHRH agonist affecting a receptor 
level, inducing cell cycle arrest, inhibiting proliferation and apoptosis and thereby 
reducing the efficacy of cytotoxic drugs. This negative effect, however, was not 
confirmed by the EBCTCG meta-analysis of the effect of LHRH agonists, which 
showed no significant difference in efficacy between chemotherapy used alone versus 
chemotherapy used in addition to an LHRH agonist 
8
. Nevertheless, LHRH agonists 
should not be recommended routinely but used highly selectively, preferably in 
hormone receptor negative tumours, until data are conclusive. When tamoxifen was 
added to goserelin in CMF-treated women, there was no statistically significant change 
in the proportion of menstruating women one year after stopped treatment, in contrast 
to the CMF-treated women receiving goserelin alone. The mechanism behind this is 
unclear but can be explained by the SERM properties of tamoxifen, which acts as an 
estrogen agonist or antagonist, depending on the endogenous estrogen milieu. The rates 
of amenorrhea in our study are comparable to several earlier studies, where CMF 
frequently induces early and irreversible amenorrhea 
74, 87, 103, 148
. The ZEBRA study 
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showed results comparable to ours, in that 65% of CMF-treated women became 
permanently amenorrheic 
74
. CMF was the standard chemotherapy regimen at the time 
of the study, whereas anthracycline based chemotherapy, with or without taxanes, have 
later replaced CMF. The extent of ovarian suppression from these agents seems similar 
or even less than from CMF 
90, 91, 97, 104, 105, 108, 109
. Our study, like most previous studies, 
used amenorrhea as a surrogate for ovarian failure. However, absence of menses is not 
an accurate measure of ovarian function. A woman can thus retain premenopausal 
status as well as fertility in spite of being amenorrheic. Likewise, a woman with regular 
menses can be infertile. Tamoxifen treatment for 5 years after cytotoxic chemotherapy 
presents a special dilemma, as tamoxifen can affect menses to a variable degree. 
Amenorrhea while on tamoxifen therapy does not equal premature menopause and 
infertility, and the effect of tamoxifen is reversible. Additional parameters of ovarian 
function, such as serum analysis of FSH, LH, anti-Müllerian hormone (AMH) and 
inhibin B, have been studied as markers of ovarian reserve but are not yet integrated 
into clinical practice 
99, 100, 175
. Poikonen et al. showed that post-chemotherapy 
menstrual status is a clinically useful marker of menstrual status, and that FSH and LH 
are less reliable 
176
 . The evaluation of serum markers, such as FSH and LH, after 
chemotherapy is therefore still under investigation. Furthermore, their use is not 
appropriate during goserelin and/or tamoxifen treatment because of gonadal 
suppression resulting in decreased levels of FSH and LH 
175, 177
. Possible confounders, 
such as the previous use of contraceptive pills as well as hormone replacement therapy 
due to menopausal symptoms, or prolonged tamoxifen treatment beyond 2 years, were 
not examined in this study.  
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5.3  PAPERS III-IV:  
Our study on bone mineral density shows that goserelin causes a 5% loss of BMD after 
2 years of treatment, but BMD partially recovers one year after stopped treatment. This 
represents rapid bone loss in young women, often many years prior to natural 
menopause, and may be an important determinant of fracture risk, as several other 
studies have shown 
132, 137, 138
. This BMD study is consistent with other reports on 
LHRH agonist and/or tamoxifen effects among premenopausal women 
142, 145, 146
. 
Treatment with tamoxifen alone resulted in a mild, yet statistically significant, decrease 
in BMD. This apparent menstrual status–dependent effect can be explained by the 
difference in endocrine milieu in which tamoxifen is acting. In premenopausal women 
a demineralising effect on bone may be caused by tamoxifen antagonizing the more 
potent activity of endogenous estrogen 
178
. Among patients treated with goserelin in 
addition to tamoxifen, the effect on bone mass was similar to that in the group treated 
with tamoxifen alone. In this group, it seems that tamoxifen at least partially 
counteracts the demineralising effects of goserelin. In premature menopause from 
LHRH agonist treatment, it seems that tamoxifen when added to goserelin has similar 
agonistic estrogenic effects on bone as in postmenopausal women. In order to estimate 
the clinical impact of a 5% bone loss from goserelin, as in our study, a 10% loss in 
BMD is equivalent to a drop in T score by 1 which in turn increases fracture risk by 2.6 
times. Therefore, we conclude that there is increased fracture risk from goserelin 
treatment although other factors play a role in bone strength 
179, 180
. 
In the study of bone turnover, the LHRH agonist goserelin increases bone turnover. 
Markers of both bone formation and bone resorption increase after 6 months of 
goserelin treatment, whereas other endocrine therapies in our study do not show 
significant bone marker changes. Tamoxifen alone or in combination with goserelin is 
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not associated with significant changes in BTM. When compared to changes in BMD, 
the changes in bone markers show an inverse association, i.e., a decrease in BMD is 
correlated to elevation of serum bone markers. The effects of goserelin on BTM and 
BMD are distinct in comparison to other endocrine therapies. The increase in markers 
of both bone formation and bone resorption is consistent with other studies, and reflect 
the instability of the microstructure of bone induced by increased bone metabolism. 
The negative effect on bone mass from LHRH agonists and tamoxifen treatment among 
premenopausal women has been reported in several studies. In a tamoxifen 
chemoprevention study Powles et al. showed an annual BMD loss of 1.4% in the 
lumbar spine 
53
. Our previous BMD study showed 5% decrease in BMD on average 
among goserelin-treated patients, whereas treatment with a combination of goserelin 
and tamoxifen or tamoxifen alone resulted in only a mild (1.4 - 1.5%) decline in BMD 
52
. Vehmanen et al. showed a similar effect of tamoxifen on bone loss, where women 
not achieving amenorrhea after chemotherapy developed bone loss from tamoxifen, 
whereas tamoxifen decreased bone loss among those achieving amenorrhea 
147
. The 
ABCSG-12 study showed an even greater loss of bone (11% in the lumbar spine and 
7% in the hip) for those treated with combined goserelin and tamoxifen, and tamoxifen 
did not seem to have a counterbalancing effect to the same extent as seen in our study 
69
. Moreover, the ABCSG-12 study showed a survival benefit from the use of the 
bisphosphonate zoledronic acid, an effect which needs to be confirmed in further 
studies 
143
. Several studies on bone effects from AIs in postmenopausal women have 
shown an inverse correlation between BMD and bone markers similar to that presented 
here 
155, 181, 182
. These reports show that bone loss is manageable, and the use of 
goserelin in addition to AIs should not be restricted. However, more aspects must be 
taken into consideration before recommending AIs in this setting. AIs have also been 
shown to have significantly increased association with hypercholesterolaemia and 
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cardiovascular morbidity in comparison to tamoxifen 
183
. Studies of the AIs anastrozole 
and exemestane have shown consistent and significantly more gastrointestinal 
symptoms, vaginal dryness, dyspareunia and diminished libido among women treated 
with AIs in comparison to tamoxifen 
184-186
. At present, BMD measurements of the 
spine and hip are generally regarded as the method of choice for assessing fracture risk 
because of the frequency of fractures and their morbidity at these sites. This study was 
initiated before this was widely accepted. Therefore, it may be a limitation of our study 
that we did not measure BMD at the spine or hip. However whole-body measurements 
have advantages, such as detection of small changes with higher sensitivity than 
regional measurements 
187
. Several investigators have shown a strong correlation on 
group level between whole-body BMD and BMD measurements at the hip or the spine 
188, 189
. Whole-body measurements of BMD can therefore be used to detect bone loss as 
a systemic disease that is not limited to the axial skeleton 
179, 190, 191
. In the past, a 
variety of bone markers have been examined besides OC, PINP and CTX as in our 
study. Bone-specific alkaline phosphatase (bone ALP), a relatively specific marker of 
bone formation, has also been widely used. Newer markers, such as such as tartrate-
resistant acid phosphatase type 5b (TRAcP-5b), osteoprotegerin (OPG) as well as bone 
sialoproteins (BSP), have been described. There has however been a lack of consensus 
on the use of bone markers in clinical practice, and BMD examinations remain to date 
the standard assessment of bone mass changes. Nevertheless, the International 
Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry 
and Laboratory Medicine (IFCC) have recently recommended the use of PINP as a 
marker of bone formation and CTX as a marker of bone resorption for BTM in clinical 
studies 
192
. A strength of our study, despite its limited sample size, is the use of these 
markers. In addition, all analyses were performed at one laboratory, which minimizes 
the risk of laboratory inconsistencies. The blood samples, however, were not collected 
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in the fasting state, which may have influenced results, as CTX in particular is highly 
influenced by dietary intake and circadian rhythm. In the studies of bone mineral 
density and bone turnover, data on possible confounders, such as smoking, calcium, 
vitamin D intake, and physical exercise, were unavailable. Another limitation of our 
study on bone markers is that due to the small number of patients undergoing blood 
tests at the predefined interval, analysis past 6 months of treatment was impossible. 
Although the follow-up was short in our study, Rogers et al. have shown earlier that the 
rate of bone loss is most rapid in the early menopausal period 
193
. Furthermore, studies 
of women with endometriosis have shown high bone turnover after only 3 to 6 months 
of goserelin treatment, followed by a decline in BMD 
194, 195
. A variety of earlier studies 
of HRT-treated postmenopausal women have similarly shown that a decrease in bone 
turnover markers within 6 months correlates significantly with an increase in BMD 
after 1-2 years 
134-136, 154
. The 6 months of follow up presented here may therefore be 
adequate and give clear indications for evaluating therapy-induced bone loss. 
Endocrine-induced bone loss with subsequent risk of osteopenic fractures is among the 
side effects that can be prevented by early use of interventions. Several studies have 
shown the positive effect of bisphosphonate treatment, especially if used from the start 
of OA therapy 
142, 143, 147, 152
.  
In summary, goserelin is effective in reducing the risk of recurrence and improving 
survival in endocrine-responsive premenopausal breast cancer. These effects are not 
enhanced by the addition of tamoxifen, and there is a significant interaction between 
goserelin and tamoxifen. Quality of life is affected by goserelin, and its side effects are 
considerable, but they are manageable and, moreover, reversible. A meta-analysis from 
the Overview group has earlier suggested that younger women may benefit more than 
older premenopausal women from LHRH agonist treatment 
8
. 
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Our study indicates that there may be an additional subgroup of women besides the 
very young, i.e., those with strongly ER-positive tumours, who benefit more from 
goserelin treatment, whereas the effect of tamoxifen does not seem to be modified by 
ER content. A significant interaction indicates that the effect of goserelin depends on 
whether tamoxifen is given or not, and the effect of tamoxifen depends on whether 
goserelin is given or not. Our data support that there is no additional benefit from 
combination endocrine therapy in the premenopausal setting. Within the limitations of 
the exploratory approach and its limited power as a stand-alone trial, our results should 
be viewed mainly as hypothesis-generating, awaiting data from ongoing trials. 
Our study shows that the addition of LHRH agonist to goserelin alone may prevent 
permanent amenorrhea for some women receiving cytotoxic chemotherapy. Young 
breast cancer patients should therefore not only receive adequate information on 
possible long-term risks of chemotherapy therapy but should as well be considered for 
optional goserelin treatment when future fertility is strongly desired. Our studies on 
bone effects show that treatment with the LHRH agonist goserelin results in substantial 
decrease of BMD and higher bone turnover in breast cancer patients. Tamoxifen seems 
to neutralize the effect of goserelin in regard to BTM as well as BMD. Furthermore, 
our results show a clear association of changes in BTM and BMD after only 6 months 
of endocrine treatment. We therefore conclude that bone marker examinations may 
predict bone loss in therapy-induced OA. These markers, in addition to BMD, can be 
used to improve the identification of women at high risk for rapid bone loss and make 
early interventions possible. 
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6 CONCLUSIONS 
 
I: Adjuvant tamoxifen, in combination with the LHRH agonist goserelin, is not superior 
to either tamoxifen alone or goserelin alone in regard to recurrence-free survival in 
premenopausal endocrine-responsive breast cancer. A significant interaction indicates 
that the effect of goserelin depends on whether tamoxifen is given or not, and the effect 
of tamoxifen is dependent on whether goserelin is given or not. 
 
II: In our study, there is a trend towards greater efficacy of goserelin with increasing 
ER levels. A subgroup of women with strongly ER-positive tumours benefits more 
from goserelin treatment, whereas the benefit of tamoxifen does not seem to be 
dependent on ER content.  
 
III: In our study, there is some evidence of goserelin's protective effect on ovarian 
function in CMF-treated women. This effect was not observed where tamoxifen was 
given in addition to goserelin treatment. 
 
IV: Two years of ovarian ablation from goserelin treatment induces a significant 
reduction in bone mineral density, but there is partial recovery from the bone loss one 
year after stopped treatment.  
 
V: The addition of tamoxifen partially counteracts the demineralising effects of 
goserelin. 
 
VI: After six months of goserelin treatment, there is an increase in markers of both 
bone resorption and bone formation, whereas there is no change in bone turnover from 
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tamoxifen alone or in combination with goserelin. In our study, there is an inverse 
correlation of changes in BMD and bone markers. In addition to BMD measurements, 
biochemical examinations of bone turnover markers may be useful for monitoring bone 
health, identifying women at risk for bone loss and making early interventions possible 
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7 FUTURE ASPECTS 
 
In spite of extensive earlier research, there are still many unanswered questions and 
challenges remaining regarding estrogen effects and endocrine treatment. Regarding the 
Stockholm cohort of the ZIPP study, there are plans to further analyse frozen tumour 
material in search of possible predictive factors. Another research area is how the 
development of resistance to endocrine therapy in breast cancer can be prevented or 
reversed. Intracellular signalling pathways, such as the phosphatidylinositol 3-kinase 
(PI3K)–Akt–mammalian target of rapamycin (mTOR), play a role in tumour 
progression in breast cancer. Ligand-independent receptor activation of the ER is 
regulated by a substrate of mTOR 
196, 197
. Drugs targeted to inhibit these pathways in 
order to reverse resistance are in development, and some already have proven clinical 
benefit, such as the selective inhibitor of the (mTOR) drug everolimus
198
. Src family 
tyrosine kinase inhibitors are also involved in several signalling pathways in breast 
cancer, such as ER and HER-2 under investigation 
199, 200
. Drugs of this class, such as 
dasatinib, are being tested in ongoing trials among hormone receptor positive and HER-
2 normal/positive patients. Among hypotheses tested in ongoing trials are endocrine 
therapy “drug holidays”, designed to examine if endocrine resistance development can 
be prevented and efficacy increased. This concept may possibly impact long-term side 
effect profiles as well as compliance. 
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